Pancreatic Cancer Risk in Glycemically Defined New-Onset Diabetes

I appreciate the excellent prospective study by Chari et al,1 examining the association between glycemically defined new-onset diabetes (GNOD) and risk of pancreatic cancer. The findings provide valuable insights into an important high-risk group for sporadic pancreatic cancer (SPC).

Cost-effectiveness analyses have suggested that early-detection programs become viable when 3-year SPC incidence exceeds 2%, and at least 25% of SPC are detected at a localized stage. Therefore, I would like to raise 2 points not explicitly discussed in the article.